Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2014

View Archived Issues

Novartis presents data on novel, highly potent p53/Mdm2 inhibitor for cancer

Novel PARP inhibitor demonstrates potent antitumor activity in various tumor xenograft models

Encouraging efficacy and safety results for ISIS-SMNRx in infants with type I SMA

Cepham develops novel green coffee bean extract for weight management

Results of a phase II study of the PsA-TT vaccine in infants with meningococcal disease

Merck & Co. presents novel IRAK-4 inhibitors for cancer and other disorders

Children's Oncology Drug Alliance formed to develop neuroblastoma treatment

Auven Therapeutics signs license agreement with Mount Sinai

Lundbeck receives funding to research LRRK2-based biomarkers in Parkinson's disease

Sanofi reports achievements of first quarter 2014

Debiopharm and Yale sign license and research agreement for MIF inhibitors

Regeneron and Avalanche Biotechnologies enter gene therapy collaboration

Discovery of a novel small-molecule inhibitor for the treatment of malaria

Secutech International designs new agents for dermatological disorders

Novel thrombin inhibitors disclosed by Merck & Co. and Albany Molecular Research

Novel P2X7 receptor antagonists designed by Lundbeck

Astellas and Medivation receive FDA priority review for Xtandi sNDA

Low-dose suvorexant safe and effective in elderly and nonelderly adults with primary insomnia

MolMed reports data from phase III trial in malignant pleural mesothelioma

Cytomedix announces data from RECOVER-Stroke study

Yakult Honsha completes phase I study of resminostat in Japan

GeneSight Psychotropic test for antidepressant and antipsychotic treatment decisions expanded

FDA approves IND for Epidiolex in Dravet syndrome

Bayer and Merck & Co. sign consumer business deal and collaborate on sGC modulators

Immune Response BioPharma outlines plans for Remune

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...